BOSTON (

TheStreet

) -- A calendar of important, potentially stock-moving biotech events for December:

Dec. 1

  • FDA approval decision date for Dyax's (DYAX) Kalbitor in hereditary angiodema.

Dec. 2

Dec. 3

  • OSI Pharmaceuticals( OSIP) analyst/investor meeting
  • Isis Pharmaceuticals (ISIS) analyst/investor meeting

Dec. 4.

  • FDA approval decision date for Somaxon Pharmaceutical's( SOMX) Silenor in insomnia

Dec. 5-8

  • American Society of Hematology annual meeting

Dec. 9-13

  • San Antonio Breast Cancer Symposium

Dec. 10

  • FDA advisory committee meeting for Gilead Sciences' (GILD) - Get Report aztreonam lysine in cystic fibrosis
  • Eli Lilly (LLY) - Get Report analyst/investor meeting

Dec. 12

  • FDA approval decision date for Vion Pharmaceuticals' (VION.OB) Onrigin in acute myelogenous leukemia
  • ImmunoGen (IMGN) - Get Report and Roche: Results from phase II study of trastuzumab-DM1 in third-line metastatic breast cancer

Dec. 16

  • FDA advisory committee meeting for OSI Pharmaceuticals' Tarceva in first-line non-small cell lung cancer

Dec. 29

  • FDA approval decision date for Cephalon's( CEPH) Nuvigil in jet lag disorder

Important clinical trials with potential data readouts or other biotech events expected in December:

  • Gilead Sciences: Results from a phase III study of darusentan in resistant hypertension
  • FDA approval decision date for Auxillium Pharmaceuticals' (AUXL) Xiaflex for Dupuytren's Contracture. (With Pfizer (PFE) - Get Report as marketing partner.)
  • Arena Pharmaceuticals (ARNA) - Get Report submission of FDA approval application for lorcaserin in obesity
  • BioDelivery Sciences (BDSI) - Get Report: Results from a phase II study of BEMA buprenorphine in dental pain
  • Synta Pharmaceuticals (SNTA) : Results from a phase II study of apilimod in rheumatoid arthritis
  • Vivus (VVUS) - Get Report submission of FDA approval application for Qnexa in obesity

-- Reported by Adam Feuerstein in Boston

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.